Amgen Inc. $AMGN Holdings Raised by Lbp Am Sa

Lbp Am Sa boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 108.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 51,776 shares of the medical research company’s stock after acquiring an additional 26,897 shares during the quarter. Lbp Am Sa’s holdings in Amgen were worth $16,947,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Reyes Financial Architecture Inc. lifted its position in Amgen by 3.5% in the 4th quarter. Reyes Financial Architecture Inc. now owns 996 shares of the medical research company’s stock worth $326,000 after buying an additional 34 shares in the last quarter. Forbes Financial Planning Inc. purchased a new stake in Amgen in the 4th quarter worth approximately $210,000. Annex Advisory Services LLC lifted its position in Amgen by 17.6% in the 4th quarter. Annex Advisory Services LLC now owns 12,757 shares of the medical research company’s stock worth $4,176,000 after buying an additional 1,905 shares in the last quarter. Foster Victor Wealth Advisors LLC lifted its position in Amgen by 2.6% in the 4th quarter. Foster Victor Wealth Advisors LLC now owns 61,202 shares of the medical research company’s stock worth $20,222,000 after buying an additional 1,541 shares in the last quarter. Finally, Bernardo Wealth Planning LLC purchased a new stake in Amgen in the 4th quarter worth approximately $210,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

NASDAQ:AMGN opened at $348.22 on Thursday. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The firm’s fifty day simple moving average is $363.86 and its 200 day simple moving average is $336.66. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The firm has a market capitalization of $187.93 billion, a PE ratio of 24.47, a PEG ratio of 3.30 and a beta of 0.47.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same period last year, the business posted $5.31 EPS. Amgen’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on AMGN shares. Leerink Partners restated a “market perform” rating and set a $355.00 price target on shares of Amgen in a report on Thursday, March 5th. Cantor Fitzgerald restated a “neutral” rating and set a $350.00 price target on shares of Amgen in a report on Wednesday, April 8th. Freedom Capital downgraded shares of Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 12th. Oppenheimer set a $400.00 price target on shares of Amgen and gave the company an “outperform” rating in a report on Thursday, January 29th. Finally, Barclays started coverage on shares of Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Amgen presently has an average rating of “Hold” and an average target price of $356.24.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.